[go: up one dir, main page]

Follow
William Lockwood
William Lockwood
Distinguished Scientist, British Columbia Cancer Agency - Professor, University of British Columbia
Verified email at bccrc.ca - Homepage
Title
Cited by
Cited by
Year
PIK3CA mutations and copy number gains in human lung cancers
H Yamamoto, H Shigematsu, M Nomura, WW Lockwood, M Sato, ...
Cancer research 68 (17), 6913-6921, 2008
5842008
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
WW Lockwood, K Zejnullahu, JE Bradner, H Varmus
Proceedings of the National Academy of Sciences 109 (47), 19408-19413, 2012
4182012
Lung cancer cell lines as tools for biomedical discovery and research
AF Gazdar, L Girard, WW Lockwood, WL Lam, JD Minna
Journal of the National Cancer Institute 102 (17), 1310-1321, 2010
3242010
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
JKM Lim, A Delaidelli, SW Minaker, HF Zhang, M Colovic, H Yang, ...
Proceedings of the National Academy of Sciences 116 (19), 9433-9442, 2019
3232019
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells
J Soh, N Okumura, WW Lockwood, H Yamamoto, H Shigematsu, ...
PloS one 4 (10), e7464, 2009
2792009
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines
J Gandhi, J Zhang, Y Xie, J Soh, H Shigematsu, W Zhang, H Yamamoto, ...
PloS one 4 (2), e4576, 2009
2472009
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
EA Marshall, KW Ng, SHY Kung, EM Conway, VD Martinez, EC Halvorsen, ...
Molecular cancer 15 (1), 67, 2016
2442016
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
AM Unni, WW Lockwood, K Zejnullahu, SQ Lee-Lin, H Varmus
Elife 4, e06907, 2015
2182015
TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer
DT Starczynowski, WW Lockwood, S Deléhouzée, R Chari, J Wegrzyn, ...
The Journal of clinical investigation 121 (10), 4095-4105, 2011
2182011
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
A Drilon, R Somwar, BP Mangatt, H Edgren, P Desmeules, A Ruusulehto, ...
Cancer discovery 8 (6), 686-695, 2018
2082018
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Y Xue, B Meehan, Z Fu, XQD Wang, PO Fiset, R Rieker, C Levins, T Kong, ...
Nature communications 10 (1), 557, 2019
2062019
Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines
R Somwar, H Erdjument-Bromage, E Larsson, D Shum, WW Lockwood, ...
Proceedings of the National Academy of Sciences 108 (39), 16375-16380, 2011
1822011
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models
A Taguchi, K Politi, SJ Pitteri, WW Lockwood, VM Faça, K Kelly-Spratt, ...
Cancer cell 20 (3), 289-299, 2011
1802011
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
T Kubo, H Yamamoto, WW Lockwood, I Valencia, J Soh, M Peyton, M Jida, ...
International journal of cancer 124 (8), 1778-1784, 2009
1682009
Recent advances in array comparative genomic hybridization technologies and their applications in human genetics
WW Lockwood, R Chari, B Chi, WL Lam
European Journal of Human Genetics 14 (2), 139-148, 2006
1622006
High resolution analysis of non‐small cell lung cancer cell lines by whole genome tiling path array CGH
C Garnis, WW Lockwood, E Vucic, Y Ge, L Girard, JD Minna, AF Gazdar, ...
International Journal of Cancer 118 (6), 1556-1564, 2006
1602006
DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers
WW Lockwood, R Chari, BP Coe, L Girard, C Macaulay, S Lam, ...
Oncogene 27 (33), 4615-4624, 2008
1482008
Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
K Suzawa, M Offin, D Lu, C Kurzatkowski, M Vojnic, RS Smith, JK Sabari, ...
Clinical Cancer Research 25 (4), 1248-1260, 2019
1472019
Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma
WW Lockwood, R Chari, BP Coe, KL Thu, C Garnis, CA Malloff, ...
PLoS medicine 7 (7), e1000315, 2010
1322010
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
AM Unni, B Harbourne, MH Oh, S Wild, JR Ferrarone, WW Lockwood, ...
Elife 7, e33718, 2018
1192018
The system can't perform the operation now. Try again later.
Articles 1–20